Can't Please Everybody: FDA's "Brief Summary" Redesign May Require Flexibility
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug Facts Box format scored well in a broad study, but researchers found it may not be the best format for everyone.
You may also be interested in...
Should FDA Make Patients Care About A Problem If They Don’t Already?
FDA’s Risk Communication Advisory Committee discusses best ways to communicate uncertainty, including how aggressive FDA should be with groups that are not engaged in its messages.
Risk Communication Panel To Continue Discussion Of Uncertainty Messaging
FDA looking for more help from advisory committee on how much information about uncertainty to give as well as how best to communicate it to minority, uneducated groups.
Rx Safety Communication In Face Of Uncertainty, Multiple Risks, To Be Examined By FDA Panel
FDA’s Risk Communication Advisory Committee will delve into research on communicating uncertainty and how individuals perceive risk and seek information when confronted with multiple risks, during a June 29 meeting.